Veeco Instruments Q2 Profit Drops

Veeco Instruments (VECO) reported a weaker Q2 2025, with net sales declining to $166.1 million from $175.9 million year-over-year, and GAAP net income falling to $11.7 million ($0.20/share) from $14.9 million. Adjusted net income also decreased to $21.5 million ($0.36/share). Looking ahead, VECO forecasts Q3 2025 revenue between $150 million and $170 million, with non-GAAP diluted EPS projected at $0.20 to $0.35. Despite the Q2 downturn, the stock saw a 1.71% gain in after-hours trading.

Analysis

Veeco Instruments (VECO) reported a contraction in its second-quarter 2025 financial performance, with key metrics declining year-over-year. Net sales fell to $166.1 million from $175.9 million, while both GAAP net income (down to $11.7 million from $14.9 million) and non-GAAP adjusted net income (down to $21.5 million from $25.4 million) also decreased. The company's forward guidance for the third quarter suggests this weakness may persist or intensify. The Q3 revenue forecast of $150 million to $170 million, with a midpoint of $160 million, indicates a potential sequential decline. Similarly, the projected non-GAAP diluted EPS range of $0.20 to $0.35 has a midpoint ($0.275) significantly below the $0.36 just reported for Q2. Paradoxically, despite the negative results and soft guidance, VECO's stock traded 1.71% higher in after-hours activity, implying that the market may have anticipated an even weaker outcome or that current valuations had already priced in the downturn.

Key Decisions for Investors

• Investors should note the clear negative trend in VECO's fundamentals, as evidenced by year-over-year declines in Q2 revenue and profit, and a Q3 forecast that points to continued weakness.
• The positive after-hours stock reaction in the face of poor results suggests negative expectations may have been priced in, but this disconnect between fundamentals and price action warrants monitoring for a potential reversal if sentiment shifts.
• Performance against the company's Q3 guidance will be a critical catalyst; failure to achieve the upper end of the revenue ($170M) and non-GAAP EPS ($0.35) ranges could lead to a negative re-evaluation of the stock.